For roughly three decades, tens of millions of people have been told that their depression is caused by a chemical imbalance in the brain, specifically a shortage of serotoninA neurotransmitter that relays signals between neurons in the brain, involved in mood regulation, sleep, appetite, and other functions.. The phrase appears in pharmaceutical advertisements, doctor’s office pamphlets, and casual conversation with equal confidence. According to surveys, approximately 85 to 90 percent of the public in North America believes this explanation. The serotonin myth persists despite one fundamental problem: the scientific evidence for it has always been thin, and a landmark 2022 review found no consistent support for the hypothesis at all.
This article covers where the serotonin myth came from, how it was marketed to the public, what the research actually shows, and why the answer matters for how we understand and treat depression. This is a YMYL (Your Money or Your Life) health topic, so a note upfront: nothing here constitutes medical advice, and no one should change their medication based on an article. If you take antidepressants, talk to your doctor before making any changes.
Where the Hypothesis Came From
The story starts in 1965, when Harvard psychiatrist Joseph Schildkraut published “The Catecholamine Hypothesis of Affective Disorders” in the American Journal of Psychiatry. It became the most cited article in the journal’s history. Schildkraut proposed that depression was associated with a deficiency of catecholamines (primarily norepinephrine) at key brain synapses. A parallel hypothesis soon emerged focusing on serotonin, another monoamine neurotransmitter. Together, these became the “monoamine hypothesis” of depression.
It is worth understanding what Schildkraut actually wrote, because it was more cautious than what came later. His paper was titled “a review of supporting evidence,” and he acknowledged the hypothesis was preliminary. He was mapping a direction for research, not announcing a proven mechanism. The serotonin version of this idea was similarly tentative when first proposed. It was a working hypothesis, the kind of provisional framework that science uses to organize inquiry.
What happened next was not science. It was marketing.
How a Hypothesis Became a Sales Pitch
Fluoxetine, marketed as Prozac, received FDA approval in December 1987. It was the first selective serotonin reuptake inhibitor (SSRI) to reach the US market. SSRIs work by blocking the reabsorption of serotonin in the brain, leaving more of it available in the synaptic cleftThe tiny gap between two neurons where neurotransmitters are released and received, enabling communication between brain cells. between neurons. The mechanism was real. What was not established was whether low serotonin caused depression in the first place.
Prozac became one of the most commercially successful pharmaceuticals in history. By 1994, it accounted for roughly $2 billion in annual sales, nearly a third of Eli Lilly’s total revenue. Sales peaked at $2.8 billion in 1998, and by 2000, approximately 40 million people worldwide had taken it.
The commercial success was built partly on a simple, memorable narrative: depression is a chemical imbalance, and this pill fixes it. In 1997, the FDA relaxed its rules on direct-to-consumer (DTC) pharmaceutical advertising, allowing broadcast ads to reference a website or phone number for full prescribing information rather than listing every risk on screen. Pharmaceutical advertising spending roughly tripled, from about $400 million to $1.2 billion in a single year. The serotonin myth had found its megaphone.
Pfizer’s television advertisements for sertraline (Zoloft) told viewers that “depression is a serious medical condition that may be due to a chemical imbalance” and that “Zoloft works to correct this imbalance.” Paxil’s marketing promised that “with continued treatment, Paxil can help restore the balance of serotonin.” These were not fringe claims. They were prime-time television spots seen by millions. The disconnect between what the ads stated and what the peer-reviewed literature supported was, as researchers Jeffrey Lacasse and Jonathan Leo wrote in a 2005 PLOS Medicine analysis, “remarkable, and possibly unparalleled.”
What the Science Actually Found
In July 2022, Joanna Moncrieff and colleagues at University College London published a systematic umbrella review in Molecular Psychiatry, one of the field’s most respected journals. The paper examined the six main pillars of the serotonin hypothesis across 17 studies, including systematic reviews, meta-analyses, and large genetic studies. It is the most comprehensive assessment of the hypothesis to date.
The findings, area by area:
- Serotonin metabolites (5-HIAA) in body fluids: Two meta-analyses found no association between serotonin metabolite levels and depression.
- Plasma serotonin levels: A meta-analysis of 1,869 participants found no relationship with depression. It did find that lower serotonin was associated with antidepressant use, suggesting the drugs themselves may reduce serotonin levels over time.
- Serotonin 5-HT1A receptor binding: Two meta-analyses (largest sample: 561) showed “weak and inconsistent evidence.”
- Serotonin transporter (SERT) binding: Three meta-analyses (largest sample: 1,845) produced weak and inconsistent results, complicated by the inability to exclude effects of prior antidepressant use.
- Tryptophan depletion studies: If low serotonin caused depression, then artificially depleting serotonin’s precursor (tryptophan) should induce depressive symptoms. In 566 healthy volunteers, it largely did not. There was weak evidence of an effect in the 75 participants with a family history of depression.
- Serotonin transporter gene (5-HTTLPR): The two largest, highest-quality genetic studies (covering 115,257 and 43,165 participants respectively) found no evidence of an association between the serotonin transporter gene and depression.
Moncrieff’s overall conclusion: “The main areas of serotonin research provide no consistent evidence of there being an association between serotonin and depression, and no support for the hypothesis that depression is caused by lowered serotonin activity or concentrations.”
The review received methodological criticism from some researchers, notably from King’s College London, who argued that the umbrella review format was not the right tool for this question and that the authors summarized existing results rather than conducting new analyses. These critiques are worth reading. But the core finding, that decades of research have not produced consistent evidence for the serotonin hypothesis, was not seriously disputed even by the critics. The debate was about how much weight to assign the negative evidence, not about whether positive evidence had been hiding somewhere.
The Gap Between the Ads and the Evidence
Lacasse and Leo’s 2005 PLOS Medicine paper documented what they called a “disconnect between the advertisements and the scientific literature” that was already clear by the mid-2000s. At the time, the DSM-IV and major psychiatric textbooks listed the serotonin hypothesis as unconfirmed. Leading researchers in the field acknowledged its limitations. Yet consumer-facing ads continued to present chemical imbalance as established science.
The paper noted several inconvenient facts the ads omitted. Exercise had been shown to match sertraline’s effectiveness in clinical trials. Bupropion and reboxetine, which do not primarily target serotonin, were effective antidepressants. St. John’s Wort had outperformed SSRIs in some studies. If depression were simply a serotonin problem, none of these results would make sense.
Perhaps most telling: there has never been an established “correct” level of serotonin in the brain. The ads spoke of “restoring balance,” but no baseline of balance was ever defined. You cannot correct an imbalance if you have never measured what balance looks like. As the placebo effect research has demonstrated in adjacent territory, the gap between what we assume about brain chemistry and what we can actually measure remains substantial.
So Do Antidepressants Work?
This is where the conversation gets genuinely complicated, and where many popular accounts of the serotonin myth go wrong.
The fact that the serotonin hypothesis lacks support does not mean SSRIs are ineffective. Those are two different questions. A drug can work through mechanisms we do not fully understand. Aspirin reduced fevers for decades before anyone explained how.
Andrea Cipriani and colleagues published a landmark network meta-analysis in The Lancet in 2018, examining 522 randomized controlled trials with 116,477 participants across 21 antidepressant drugs. The finding: all 21 antidepressants were more effective than placebo. That is a meaningful result.
But the size of the effect matters. The overall standardized mean difference was 0.30, which falls in the “small” effect sizeA standardized measure of the magnitude of difference between groups in a study, independent of sample size. range. Irving Kirsch’s earlier meta-analysis of FDA trial data, published in PLOS Medicine in 2008, found that SSRIs improved depression scores by an average of 1.8 points more than placebo on the Hamilton Rating Scale. The UK’s National Institute for Health and Care Excellence (NICE) has defined a clinically significant benefit as a drug-placebo difference of 3 points on that scale. By that benchmark, the average SSRI benefit fell short of clinical significance, except in the most severely depressed patients.
None of this means antidepressants are useless. For some people, particularly those with severe depression, the evidence of benefit is clear. For mild to moderate depression, the picture is murkier, and the question of whether the benefit exceeds placebo by a clinically meaningful margin remains genuinely contested among researchers. This is exactly the kind of expert disagreement driven by structural mechanisms rather than one side being simply wrong.
Why the Serotonin Myth Stuck
A hypothesis with weak evidence does not survive for three decades by accident. Several forces sustained the serotonin myth long past its evidential expiry date.
It was useful for patients. “You have a chemical imbalance” is destigmatizing. It reframes depression as a medical condition rather than a personal failing. Telling someone their brain chemistry is off is kinder than telling them to try harder. The serotonin myth was, for many people, the first framework that made their suffering feel legitimate.
It was useful for doctors. General practitioners prescribe the majority of antidepressants, often in 15-minute appointments. A simple biochemical explanation gives both doctor and patient a shared model and a clear treatment path: take this pill, fix the imbalance. The reality, that depression likely involves inflammation, stress hormones, neural plasticity, gut microbiome interactions, social circumstances, and mechanisms we have not identified yet, does not fit on a prescription pad.
It was useful for pharmaceutical companies. A chemical imbalance with a chemical fix is the ideal marketing narrative. It makes the product feel necessary rather than optional. As the history of regulatory captureThe process where a regulated industry shapes the legislation meant to regulate it, often resulting in rules that benefit the industry more than the public interest. illustrates, the pharmaceutical industry’s relationship with the agencies that oversee it has structural features that make this kind of narrative persistence predictable.
It was difficult to disprove cleanly. The monoamine hypothesis is not one claim; it is a family of related claims about multiple neurotransmitters, receptors, transporters, and genes. Each negative finding could be met with “but we haven’t tested the right version yet.” This is scientifically reasonable up to a point, but after decades of negative results across all major avenues, the burden of proof has shifted.
What Depression Probably Is
If not a serotonin deficiency, then what? The honest answer is that we do not have a single replacement theory, and pretending otherwise would be repeating the same mistake.
Current research points to depression as a condition involving multiple interacting systems. Chronic stress elevates cortisol, which can damage the hippocampus and reduce neuroplasticityThe brain's ability to reorganize and form new neural connections throughout life in response to learning, experience, or injury.. Inflammation markers are elevated in a significant subset of depressed patients. The gut-brain axis, mediated partly by the microbiome, appears to influence mood through pathways we are only beginning to map. Social isolation, childhood adversity, sleep disruption, and chronic pain all increase depression risk through mechanisms that do not reduce to any single neurotransmitter.
The emerging picture is less satisfying than “chemical imbalance” because it is harder to explain in a television ad and harder to treat with a single drug. But it is more consistent with the evidence, and it opens the door to treatments (psychotherapy, exercise, anti-inflammatory interventions, social prescribing) that the serotonin myth implicitly marginalized by framing depression as fundamentally pharmacological.
What This Means Going Forward
The serotonin myth matters beyond academic interest for three reasons.
First, informed consentAn ethical and legal requirement in research that participants must be fully informed about the nature, risks, benefits, and procedures of a study, and must voluntarily agree to participate without coercion or misrepresentation. A key principle in research ethics.. Patients who were told they had a chemical imbalance were given a false certainty about a mechanism that was never established. They made treatment decisions on that basis. Some of those decisions were good ones (SSRIs help many people), but the reasoning behind them was flawed. Patients deserve accurate information about what is known and what is not.
Second, treatment diversity. If depression is not simply a serotonin problem, then serotonin-targeting drugs should not be the default first-line treatment for all cases. Exercise, cognitive behavioral therapy, and other interventions have evidence bases that compare favorably to SSRIs for mild to moderate depression. The serotonin myth crowded out these alternatives by making them seem like lesser options.
Third, scientific humility. A provisional hypothesis was marketed as established fact for profit. The institutions that should have corrected this, medical schools, regulatory agencies, professional societies, were slow to do so. Understanding how this happened is essential to preventing it from happening with the next oversimplified neurochemical narrative.
The serotonin myth was not a conspiracy. It was a convergence of commercial incentives, genuine therapeutic hope, patient need, and a catchy explanation that felt true. Dismantling it does not require cynicism about psychiatry or hostility toward medication. It requires the same thing all good science requires: following the evidence even when the story it tells is less neat than the one we were sold.
Disclaimer: This article discusses the scientific evidence regarding the serotonin hypothesis of depression. It is not medical advice. If you are currently taking antidepressants, do not stop or change your medication without consulting your doctor. Depression is a serious medical condition, and treatment decisions should be made with a qualified healthcare provider.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional regarding any mental health concerns, diagnoses, or treatment decisions.
